Document Detail

Interferon-alpha in the treatment of essential thrombocythemia.
MedLine Citation:
PMID:  8951784     Owner:  NLM     Status:  MEDLINE    
Interferon alpha (IFN) inhibits the growth of megakaryocytic progenitors in normal hematopoiesis and in patients with essential thrombocythemia (ET) leading to a reduction of peripheral platelet counts. The effectiveness in the induction therapy of patients with ET is demonstrated in 11 international studies including 212 patients. With an average dose of about 3 mill IU IFN daily, the response rate was about 90%. Further studies investigated the practicability and the success of IFN maintenance therapy. The results show that IFN can effectively control platelet counts over a period of several years. During maintenance the IFN dose could be reduced in the majority of patients. However, sustained unmaintained complete remissions were obtained in only 12% of the patients. Side effects were frequently the limiting factors in treatment with IFN especially in older patients. Analyzing a total of 273 patients, IFN therapy was terminated in 25% against the primary treatment plan. Of the currently effective drugs in controlling the platelet counts in ET, IFN is the only antiproliferative agent with immuno-modulating properties. Thus far, no leukemogenic or significant gonadotoxic effects have been observed. In a subset of the patients off all therapy, the sustained remissions support a long-term tumor load reduction effect by IFN. Thus, IFN is a promising agent in cytoreductive treatment of ET especially in younger patients.
E Lengfelder; M Griesshammer; R Hehlmann
Related Documents :
1581884 - Cytogenetic study of acute lymphoblastic leukemia and its correlation with immunophenot...
12563614 - Advanced-phase chronic myeloid leukemia.
9294964 - Two cases of hypergranular acute lymphoblastic leukemia.
10455044 - Search for cross-species transmission of porcine endogenous retrovirus in patients trea...
12892854 - Antisaccade performance is abnormal in schizophrenia patients but not in their biologic...
16774624 - Wide-range c-reactive protein efficacy in acute ischemic stroke patients.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  22 Suppl 1     ISSN:  1042-8194     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  1996 Sep 
Date Detail:
Created Date:  1997-03-20     Completed Date:  1997-03-20     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  135-42     Citation Subset:  IM    
III. Medizinische Klinik Mannheim, University of Heidelberg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Marrow / drug effects,  pathology
Clinical Trials as Topic
Follow-Up Studies
Immunologic Factors / adverse effects,  pharmacology,  therapeutic use*
Interferon-alpha / adverse effects,  pharmacology,  therapeutic use*
Megakaryocytes / drug effects,  pathology
Middle Aged
Platelet Aggregation Inhibitors / therapeutic use
Platelet Count / drug effects
Quinazolines / therapeutic use
Remission Induction
Thrombocythemia, Essential / therapy*
Reg. No./Substance:
0/Immunologic Factors; 0/Interferon-alpha; 0/Platelet Aggregation Inhibitors; 0/Quinazolines; 0/anagrelide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment--impact on ...
Next Document:  Interferon treatment in polycythaemia vera.